HCW Biologics (HCWB) reports Q1 EPS of $0.37 and $6.54M in sales. Find out why the stock skyrocketed and what's next.
HCW Biologics Inc. (NASDAQ:HCWB) stock is falling on Monday. Retail investors are taking profits following a massive 262% surge during the previous trading session.
Despite the pullback, the stock remained sharply higher overall.
Something went wrong.
Nasdaq futures are down 0.37% while S&P 500 futures have shed 0.43%.
Quarterly Financials and Pipeline Milestones
HCW Biologics shares soared Friday after the company reported stronger quarterly results, advanced a key licensing deal and…
Carter Worth takes a look at the charts for mid-cap biotech Immunovant.
Shares in Hong Kong-based Regencell Bioscience Holdings nearly quadrupled in value amid a 38-to-1 stock split despite the firm…
Carter Worth breaks down the charts on this biotech stock.
RBC's $22 price target implies an upside of 74% for shares of Biohaven.
Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.
